IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, said it is making progress across all activities.
In a statement issued ahead of today's AGM, chair of the London-listed company, Trevor Brown, said: “Progress continues steadily across all activities as prospects continue to brighten. I am looking forward to updating shareholders as the year unfolds.”
The company said it has received over 200 more datasets as part of its collaboration with Phoenix Children’s Hospital, which will be used for the development of artificial intelligence (AI) imaging technologies to aid paediatric patients.
IQ-AI said its Phase I clinical trial is enrolling subjects at the final dose level into the expansion level.
The company noted that, as part of brain tumour awareness month, Dr Jennifer Connelly will be interviewed by a local Wisconsin TV outlet later in May to showcase the Phase I clinical trial, which is taking place at the Medical College of Wisconsin.
Meanwhile, Imaging Biometrics, IQ-AI's subsidiary, is exploring two academic collaborations for the commercialisation of novel and emerging imaging technologies.